Thereby, one of the main goals of liposomes is to protect the entrapped drug while also reducing its off-site toxicity, as shown for multiple formulations. [5][6][7][8] To this end, increasing on-target tissue concentration is a key aspect which can be achieved both by nontargeted and targeted liposomes. [9][10][11][12] In this regard, a crucial point is the prolongation of systemic circulation lifetime. It is well-known that upon injection the majority of conventional (plain) liposomes are cleared rapidly from the blood stream by cells of the mononuclear phagocyte system. [13][14][15] To enhance circulation times, a variety of approaches to modify the surface of liposomes emerged, [16][17][18] yet ultimately polyethylene glycol (PEG) established itself as gold standard in the early 1990s aiming at decreasing opsonization. [19][20][21] PEGylation not only reduces but also alternates the recognition of nanoparticles by complement factors and opsonins, resulting in a decreased nanoparticle recognition and clearance by macrophages. [22,23] Manipulating opsonization, including the reduction of complement activation thus is one of the main goals in preventing rapid clearance.Today, surface modifications of liposomes are mostly realized with amphiphilic lipid-polymer conjugates like 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG2k). [24,25] Despite the benefits and being considered mostly nonimmunogenic, phospholipid-PEG conjugates have also demonstrated some drawbacks over the Circulation lifetime is a crucial parameter for a successful therapy with nanoparticles. Reduction and alteration of opsonization profiles by surface modification of nanoparticles is the main strategy to achieve this objective. In clinical settings, PEGylation is the most relevant strategy to enhance blood circulation, yet it has drawbacks, including hypersensitivity reactions in some patients treated with PEGylated nanoparticles, which fuel the search for alternative strategies. In this work, lipopolysarcosine derivatives (BA-pSar, bisalkyl polysarcosine) with precise chain lengths and low polydispersity indices are synthesized, characterized, and incorporated into the bilayer of preformed liposomes via a post insertion technique. Successful incorporation of BA-pSar can be realized in a clinically relevant liposomal formulation. Furthermore, BA-pSar provides excellent surface charge shielding potential for charged liposomes and renders their surface neutral. Pharmacokinetic investigations in a zebrafish model show enhanced circulation properties and reduction in macrophage recognition, matching the behavior of PEGylated liposomes. Moreover, complement activation, which is a key factor in hypersensitivity reactions caused by PEGylated liposomes, can be reduced by modifying the surface of liposomes with an acetylated BA-pSar derivative. Hence, this study presents an alternative surface modification strategy with similar benefits as the established PEGylation of nanoparticles, but with the potential...